Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Peter Ferenci"'
Autor:
David Chromy, David J. M. Bauer, Benedikt Simbrunner, Matthias Jachs, Lukas Hartl, Philipp Schwabl, Caroline Schwarz, Armin Rieger, Katharina Grabmeier‐Pfistershammer, Michael Trauner, Peter Ferenci, Mattias Mandorfer, Michael Gschwantler, Thomas Reiberger
Publikováno v:
Journal of viral hepatitis. 29(5)
The recently reported epidemic of acute hepatitis C virus (HCV) infections -observed predominantly among men who have sex with men (MSM)-may now decline due to wide availability of direct-acting antivirals (DAAs). This study aimed to investigate the
Autor:
David Chromy, Bernhard Scheiner, Theresa Bucsics, Markus Peck-Radosavljevic, Philipp Schwabl, Peter Ferenci, Mattias Mandorfer, Thomas Reiberger, Maximilian C. Aichelburg, Michael Trauner, Caroline Schmidbauer
Publikováno v:
United European Gastroenterology Journal. 7:507-516
BACKGROUND: The treatment of acute hepatitis C (AHC) with direct-acting antiviral agents (DAAs) is considered a cornerstone of hepatitis C virus (HCV) elimination strategies, especially in human immunodeficiency virus (HIV)-infected individuals at hi
Autor:
Teresa Binter, Philipp Schwabl, Petra Steindl-Munda, Mattias Mandorfer, Georg Semmler, Albert Friedrich Stättermayer, David Chromy, Benedikt Simbrunner, Thomas Reiberger, Karin Kozbial, Michael Trauner, Francesco Paolo Russo, Rainer Schöfl, Alberto Zanetto, David Bauer, Sabrina Gavasso, T Bucsics, Stefanie Hametner‐Schreil, Peter Ferenci, Paolo Simioni, Bernhard Scheiner, Matthias Pinter
Publikováno v:
Hepatology (Baltimore, Md.)
Background and Aims Risk stratification after cure from hepatitis C virus (HCV) infection remains a clinical challenge. We investigated the predictive value of noninvasive surrogates of portal hypertension (liver stiffness measurement [LSM] by vibrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88424ab751f0528afe93562b2be7900b
http://hdl.handle.net/11577/3351799
http://hdl.handle.net/11577/3351799
Autor:
Markus Peck-Radosavljevic, Arnulf Ferlitsch, Michael Trauner, Rafael Paternostro, A. Etschmaier, S Hametner, P. Salzl, Peter Quehenberger, Monika Ferlitsch, Thomas Reiberger, Peter Ferenci, Thomas Horvatits, Andreas Maieron, Harald Hofer, Karoline Rutter
Publikováno v:
Digestive and Liver Disease. 48:1194-1199
Treatment of chronic hepatitis C virus (HCV) infection was revolutionized within the last years. Interferon free antiviral regimens are not accessible without limitations. Combination of peginterferon/ribavirin with first generation direct acting ant
Autor:
Peter Ferenci, Tami Pilot-Matias, N. Mobashery, Jordan J. Feld, George V. Papatheodoridis, Christophe Hézode, Christophe Moreno, Tarek Hassanein, Stefan Zeuzem, Yao Yu, Roula B. Qaqish, Rebecca Redman, Tarik Asselah, Magdy Elkhashab
Publikováno v:
The Lancet Gastroenterology & Hepatology. 1:25-35
Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial d
Autor:
David Bauer, Theresa Bucsics, David Chromy, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger, Gerold Felician Lang, Caroline Schmidbauer, Peter Ferenci, Bernhard Scheiner, Thomas Szekeres, Michael Trauner
Publikováno v:
AIDS patient care and STDs. 33(5)
Human immunodeficiency virus (HIV)-induced metabolic abnormalities and antiretroviral therapy (ART), genetic factors, most importantly the rs738409 C G p.I148M variant in the patatin-like phospholipase domain containing 3 (PNPLA3)-gene, as well as he
Autor:
Gregory T. Everson, Julian Zhou, Peter Ferenci, Ellen S. Yetzer, Eric M. Yoshida, Savino Bruno, Pietro Andreone, Curtis Cooper, Nancy S. Shulman, Sophie Le Pogam, Teresita Beltran-Jaramillo, Mercidita T. Navarro, Mitchell L. Shiffman, Athina Voulgari, Isabel Najera, Christophe Hézode, Michael J. Brunda, Stefan Zeuzem
Publikováno v:
Liver International. 35:108-119
Background & Aims Danoprevir is a hepatitis C virus (HCV) protease inhibitor with activity against genotypes (G)1/G4, which is maintained at lower doses by ritonavir-boosting. We report results of a large, randomized, active-controlled phase IIb stud
Autor:
Roger Trinh, Marina Berenguer, Marcos Pedrosa, Heiner Wedemeyer, Juan Carlos Lopez-Talavera, Gregory T. Everson, Sandra S. Lovell, Peter Ferenci, Michael W. Fried, Xavier Forns, Fred Poordad, Mitchell L. Shiffman
Publikováno v:
Liver International
Background & Aims Thrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood of sus
Autor:
Mariem Charafeddine, Henning Kleine, Peter Ferenci, David Back, Suzanne Norris, Dominique Larrey, Eric Crown, Robert Flisiak, Manuela Curescu, Patrick K. Dorr, Suzanne Bourgeois, Mark Bondin, Peter Buggisch, Fiona Marra
Publikováno v:
Journal of Viral Hepatitis
JOURNAL OF VIRAL HEPATITIS
Journal of Viral Hepatitis, Wiley-Blackwell, 2019, 26 (6), pp.685-696. ⟨10.1111/jvh.13080⟩
JOURNAL OF VIRAL HEPATITIS
Journal of Viral Hepatitis, Wiley-Blackwell, 2019, 26 (6), pp.685-696. ⟨10.1111/jvh.13080⟩
International audience; Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate
Autor:
Bart Fevery, Edward Gane, Chris Corbett, Ewa Janczewska, Maria Beumont, Suzanne Bourgeois, Moisés Diago, R. Kalmeijer, Edwin DeJesus, Jacob George, Peter Ferenci, W. Jessner, Mariliza Hendrique Da Silva, Henk W. Reesink, Holger Hinrichsen, Oliver Lenz, Umesh Shukla, I. V. Nikitin
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-13 (2017)
BMC infectious diseases, 17(1). BioMed Central
BMC Infectious Diseases
BMC infectious diseases, 17(1). BioMed Central
BMC Infectious Diseases
Background This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin (RBV) in a well-characterized population of HCV genotype 1 (GT1)-infected treatm